Ambrx Biopharma is the top mid-cap pick, is the biggest gainer listed on the Dow Jones Industrial Average, while Ambrx is the tech-heavy Nasdaq’s big winner.Year to date, the S&P, Dow and Nasdaq are up 16%, 4% and 33%, respectively, rebounding from the stock market’s dreadful 2022, which saw the worst returns in 13 years.
Despite the market's headline gains, it’s been far from a banner year for all firms. The median stock listed on the S&P has returned 5%, meaning a few surging names are leading the overall rally. In fact, the weight of the S&P’s two largest components, Apple and Microsoft, is at its highest level in four decades.
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Recession will take shine off stocks' AI-fueled rally in H2: HSBCUS stocks face a painful rest of 2023 with a recession set to take the shine off the AI-fueled rally, HSBC says
Fonte: BusinessInsider - 🏆 729. / 51 Consulte Mais informação »
24 'strong-buy' stocks with most upside, including one with 340%: TipRanks24 'strong-buy' stocks with the highest potential upsides based on consensus price targets from Wall Street's top-performing analysts, according to a fintech company
Fonte: BusinessInsider - 🏆 729. / 51 Consulte Mais informação »
Fonte: WSJ - 🏆 98. / 63 Consulte Mais informação »
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »